“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

August 29, 2026 Connie Loizos

Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.

Previous Article
At TechBBQ, Europe’s AI conversations kept coming back to: Who’s actually in control?
At TechBBQ, Europe’s AI conversations kept coming back to: Who’s actually in control?

Investors, founders, and operators from across Europe arrived for the annual Nordic TechBBQ conference to t...

Next Article
Hollywood celebs are getting into microdrama apps
Hollywood celebs are getting into microdrama apps

Several Hollywood celebs are ditching the massive eight-figure checks and exotic movie sets for a rising fo...

LINK CTA

Learn More